MLTX vs. SRPT, PCVX, ASND, QGEN, ROIV, LNTH, RVMD, BBIO, AXSM, and TLX
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry.
MoonLake Immunotherapeutics vs.
Sarepta Therapeutics (NASDAQ:SRPT) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
Sarepta Therapeutics presently has a consensus target price of $170.41, indicating a potential upside of 70.94%. MoonLake Immunotherapeutics has a consensus target price of $83.20, indicating a potential upside of 126.39%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Sarepta Therapeutics.
Sarepta Therapeutics has a net margin of 7.43% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat MoonLake Immunotherapeutics' return on equity.
86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Sarepta Therapeutics received 1399 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.71% of users gave MoonLake Immunotherapeutics an outperform vote while only 75.18% of users gave Sarepta Therapeutics an outperform vote.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sarepta Therapeutics had 7 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 11 mentions for Sarepta Therapeutics and 4 mentions for MoonLake Immunotherapeutics. Sarepta Therapeutics' average media sentiment score of 0.58 beat MoonLake Immunotherapeutics' score of 0.46 indicating that Sarepta Therapeutics is being referred to more favorably in the media.
Sarepta Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
Summary
Sarepta Therapeutics beats MoonLake Immunotherapeutics on 10 of the 17 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLTX) was last updated on 3/11/2025 by MarketBeat.com Staff
Free MLTX Stock Alerts